Strongbridge Biopharma (SBBP) PT Lowered to $12 at Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros lowered the price target on Strongbridge Biopharma (NASDAQ: SBBP) to $12.00 (from $17.00) while maintaining a Overweight rating.

The analyst commented, "This morning, Strongbridge announced and held a conference call to discuss earnings from 4Q18/2018. Strongbridge reported 2018 KEVEYIS sales of $16.8 million vs. $7 million in 2017 (since April launch). Primary focus remains on the ongoing Phase 3 program for RECORLEV in Cushing's syndrome, as the company is preparing for a Type C meeting with the FDA this quarter."

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Diana Shipping withdraws bid to acquire Genco Shipping